* Autolus Therapeutics PLC AUTL.OQ AUTL.O is expected
to show
a rise in quarterly revenue when it reports results on May 4.
* The London United Kingdom-based company is expected to
report
a 112.7% increase in revenue to $353.13 thousand from $166
thousand a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Autolus
Therapeutics PLC
is for a loss of 27 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Autolus
Therapeutics PLC is $7, above its last closing price of $1.86.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.06 -0.27 -0.23 Beat 14.4
Sep. 30 2022 -0.49 -0.46 -0.47 Missed -1
Jun. 30 2022 -0.42 -0.42 -0.46 Missed -9.5
Mar. 31 2022 -0.49 -0.48 -0.41 Beat 14.8
Dec. -0.53 -0.46 -0.51 Missed -10.5
31 2021
Sep. 30 2021 -0.52 -0.51 -0.47 Beat 7
Jun. 30 2021 -0.50 -0.50 -0.47 Beat 5.8
Mar. 31 2021 -0.61 -0.60 -0.52 Beat 14
This summary was machine generated May 2 at 18:31 GMT. All
figures in US dollars unless otherwise stated